Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TREMFYA® (guselkumab)

Medical Information

+ Save link

TREMFYA - Retreatment of Active Psoriatic Arthritis after a Drug Free Interval

Last Updated: 06/05/2025

SUMMARY

The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
Please refer to the local labeling for relevant information on dosage and administration of TREMFYA.
The 2 phase 3 (DISCOVER-1 and DISCOVER-2) and the phase 3b (COSMOS) clinical trials that evaluated the efficacy and safety of TREMFYA in the treatment of active psoriatic arthritis (PsA) did not evaluate retreatment after a drug free interval.¹^-³

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and Derwent^® (and/or other resources, including internal/external databases) conducted on 5 June 2025 did not identify any relevant literature pertaining to this topic.

References

Show

1	Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial [published correction appears in Lancet. 2020;395(10230):1114]. Lancet. 2020;395(10230):1126-1136.
2	Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136.
3	Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359-369.

Endchat

Chat live